NCT05902039 is a clinical trial of MRI in Cadasil, sponsored by Peking University First Hospital.

Who is sponsoring NCT05902039?

NCT05902039 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT05902039?

Interventions in NCT05902039: MRI.

What condition does NCT05902039 study?

NCT05902039 studies Cadasil, Blood Brain Barrier Defect.

Is NCT05902039 still recruiting?

NCT05902039 is currently status unknown. Last updated 13 June 2023.

Last reviewed 2023-06-13 · How we verify

NCT05902039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI Study of Blood-brain Barrier Function in CADASIL

Status unknown Last updated 13 June 2023

What this trial tests

trial testing MRI in Cadasil in 100 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
1 April 2025

1 April 2026

Quick facts

Lead sponsor	Peking University First Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 April 2021
Primary completion	1 April 2025
Estimated completion	1 April 2026
Sites	1 location across China

Drugs / interventions tested

MRI — full drug profile →

Conditions studied

Cadasil — all drugs for Cadasil →
Blood Brain Barrier Defect — all drugs for Blood Brain Barrier Defect →

Sponsor

Peking University First Hospital

Who can join

Adults 20 to 70, any sex, with Cadasil or Blood Brain Barrier Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Restoring brain barriers: an innovative approach for treating neurological disorders.
Lemarchant S, Engelhardt B, Cicchetti F, Bix GJ, et al · · 2025 · cited 5× · PMID 40640916 · DOI 10.1186/s12987-025-00688-z
Quantitative modeling of lenticulostriate arteries on 7-T TOF-MRA for cerebral small vessel disease.
Li Z, Sun D, Ling C, Bai L, et al · · 2024 · cited 1× · PMID 39499373 · DOI 10.1186/s41747-024-00512-7
Arterial spin labeling MRI in CADASIL: Implications for cerebral small vessel disease and therapeutic trials.
Ihara M, Saito S, Fujiwara S, Tanaka T, et al · · 2026 · PMID 42028541 · DOI 10.1016/j.cccb.2026.100542

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Cadasil

Currently open trials in the same condition.

NCT05755997 — CERebrolysin In CADASIL · Phase 2 · active not recruiting
NCT06148051 — AusCADASIL: An Australian Cohort of CADASIL · recruiting
NCT05734378 — Prognosis of Cerebral Small Vessel Disease · recruiting
NCT04310098 — CADASIL Registry Study · recruiting
NCT05473637 — Taiwan Associated Genetic and Nongenetic Small Vessel Disease · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05902039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 13 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05902039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing